Abstracts tagged "Natural killer (NK) cells and rheumatoid arthritis (RA)"

Abstract Number: 2602 • ACR/ARHP Annual Meeting 2016
Anti-TNF Therapy Is Associated with an Impaired Function of NK Cells and a Defective Immunosurveillance Against B-Cell Lymphomas
Gaetane Nocturne^1,2, Bineta Ly³, Saida Boudaoud⁴, raphaèle seror^5,6, Laurence Zitvogel⁷ and Xavier Mariette^8,9, ¹Rheumatology Service, Bicêtre University Hospital, Le Kremlin Bicetre, France, ²INSERM U1184, Université Paris Sud, Le Kremlin Bicêtre, France, ³INSERM U1184, Paris Sud University, Kremlin Bicetre, France, ⁴INSERM U1184, Paris Sud University, Le Kremlin Bicêtre, France, ⁵Assistance Publique-Hôpitaux de Paris (APHP), Hôpitaux universitaires Paris Sud, Université Paris Sud, kremlin bicetre, France, ⁶INSERM U1184, Paris Sud University, Le Kremlin Bicetre, France, ⁷IGR - INSERM U1015, Villejuif, France, ⁸Department of Rheumatology, APHP - Hopitaux universitaire Paris Sud, Le Kremlin Bicetre, France, ⁹INSERM U1184, Université Paris-Sud, Paris, France, Le Kremlin Bicetre, France
Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased risk of lymphoma linked to activity of the disease. Immunosuppressive drugs have been suspected to induce…
Abstract Number: 1499 • ACR/ARHP Annual Meeting 2014
Characterization of ABT-494, a Second Generation Jak1 Selective Inhibitor
Candace Graff¹, Annette Schwartz¹, Jeffrey Voss², Neil Wishart³, Lisa Olson¹, Jonathon George³, Deborah Hyland³ and Heidi Camp⁴, ¹AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ²Immunology, AbbVie Pharmaceuticals, Worcester, MA, ³Abbvie Pharmaceuticals, worcester, MA, ⁴1101 Oak Street, Abbvie, Winnetka, IL
Background/Purpose Jak kinase blockade can effectively manage rheumatoid arthritis (RA) and in some cases achieve remission. However, first generation Jak inhibitors have not met expectations…
Abstract Number: 2374 • ACR/ARHP Annual Meeting 2013
Pharmacodynamics Of a Novel Jak1 Selective Inhibitor In Rat Arthritis and Anemia Models and In Healthy Human Subjects
Jeffrey Voss¹, Candace Graff², Annette Schwartz³, Deborah Hyland⁴, Maria Argiriadi⁴, Heidi Camp⁵, Lori Dowding⁴, Michael Friedman⁴, Kristine Frank⁵, Jonathon George⁴, Eric Goedken⁴, Gloria Lo Schiavo⁴, Michael Morytko⁴, Robert o'Brien⁴, Robert Padley⁶, Matthew Rosebraugh⁵, Michael Rozema⁵, Kent Stewart⁵, Grier Wallace⁴, Neil Wishart⁴, Anwar Murtaza⁷ and Lisa Olson³, ¹Immunology, AbbVie Pharmaceuticals, Worcester, MA, ²Drug Metabolism and Pharmacokinetics, Abbvie Pharmaceuticals, worcester, MA, ³AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ⁴Abbvie Pharmaceuticals, worcester, MA, ⁵abbvie pharmaceuticals, north chicago, IL, ⁶AbbVie, Inc, North Chicago, IL, ⁷Broad Institute, Cambridge, MA
Background/Purpose: Anti-cytokine therapies have become the mainstay of treatment for rheumatoid arthritis (RA) disease symptoms and can arrest disease progression. Despite numerous treatment options there…
Abstract Number: 1158 • ACR/ARHP Annual Meeting 2013
Decreased NK-Cell Numbers and Upregulation Of Markers Of Systemic Inflammation In Autoantibody –Positive Arthralgia Patients and Early Rheumatoid Arthritis Patients But Not In Autoantibody-Negative Rheumatoid Arthritis Patients
Paulina Chalan¹, Johan Bijzet², Kornelis S.M. van der Geest¹, Bart-Jan Kroesen³, Annemieke M.H. Boots^4,5 and Elisabeth Brouwer¹, ¹Dept. of Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ²Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ³Dept. of Laboratory Medicine, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁴Dept. of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁵Groningen Research initiative on healthy Ageing and Immune Longevity (GRAIL), Groningen, Netherlands
Background/Purpose: Identification of seropositive individuals at risk for arthritis development would open opportunities for early clinical intervention. In a recent study on seropositive arthalgia patients…
Abstract Number: 1080 • ACR/ARHP Annual Meeting 2012
Effect of Anti-NKG2A Antibody Treatment On NK Cell Receptor Expression in Rheumatoid Arthritis Patients
Joseph Wahle, John Bui and Kristen Bontadelli, Biopharmaceuticals Research Unit, Novo Nordisk, Seattle, WA
Background/Purpose: This study explored the effect of in vitroblockade of the NKG2A HLA-E interaction on peripheral NK cells from rheumatoid arthritis patients. To block this…